Loading data for FENC — first visit, this takes a few seconds.
Fennec Pharmaceuticals Inc. (FENC)
NasdaqCM: FENC
· 实时价格 · USD
10.96
-0.34 (-3.01%)
收盘价： Sep 11, 2026, 3:59 PM
10.96
+0.00%
盘后: 7:30 PM
股价、关键数字和最新消息，都在这一页。
Fennec Pharmaceuticals Inc.（FENC）股价、分析与数据
-3.01% (1D)
| 买价 | 8.1 |
| 市值 | 384M |
| 营收（TTM） | 59.2M |
| 净利润（TTM） | -3.25M |
| 1.10 | |
| -0.12 | |
| n/a | |
| 11.56 | |
| 市净率（TTM） | 9.05 |
| 市销率（TTM） | 6.49 |
| 财报日期 | Nov 12, 2026 |
| 卖价 | 14.46 |
| 成交量 | 249,926 |
| 20日均量 | 234,445 |
| 开盘价 | 11.30 |
| 前收盘价 | 11.30 |
| 日内区间 | 10.85 - 11.51 |
| 52周区间 | 5.65 - 13.25 |
| 分析师 | n/a |
| 目标价 | n/a |
| 分红 | n/a |
| 除息日 | n/a |
关于 FENC
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation,...
公司完整简介财报意外
Fennec Pharmaceuticals 已于 Aug 11, 2026 发布季度财报：
- 营收为 $17.87M 低于预期 $0, ， 85.18% 同比增长.
- 每股收益为 0.05 超出预期 0.03, ， 145.45% 同比增长.
第 1 页，共 2 页